ClinicalTrials.gg
RecruitingNCT06742125DCB-STEMIUpdated Sep 28, 2026

Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction

An interventional study of Drug-coated balloon (DCB) and Drug-eluting stent (DES) in ST-elevation Myocardial Infarction (STEMI), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Sep 28, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,244
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 41 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
21st of 97
1,244 · median 320
Started
2025
with 10 others
No phase
51 of 146
21 open now
Primary completion
2032-01
later than 40 of 42 live
Registered
118th of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 21st largest by planned enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2025, is one of 51 with no phase, reaches primary completion later than 40 of the 42 other live ones, and was the 118th registered.

ST Elevation Myocardial Infarction

851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

41 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

35 more — sign in →

All 41 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the "leave-nothing-behind" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.

Read the detailed description

Objectives of Study:

Compare the clinical outcomes of drug-coated balloon (DCB) and drug-eluting stent (DES) treatment in patients with ST-segment elevation myocardial infarction (STEMI).

Design of Study:

Investigator-Initiated,Open Label,Prospective,Multicenter,Randomized Clinical Trial.

Patients Selected: This study aims to STEMI patients who have successfully completed lesion pretreatment in multiple medical centers in China. Patients who meet the inclusion criteria and have no exclusion criteria will be randomly assigned 1:1 to the drug coated balloon group and drug eluting stent group, totaling 1244 cases (622 cases per group).

03

Conditions studied

  • ST-elevation Myocardial Infarction (STEMI)

Keywords

  • Drug-coated balloon
  • Drug-eluting stent
  • ST-elevation myocardial infarction (STEMI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. . Age of Patients ≥18 years old;
  2. Acute myocardial infarction patients with onset symptoms\<48 hours require emergency PCI;
  3. . Diagnosis: Chest pain and other ischemic symptoms accompanied by ST segment elevation in at least two adjacent leads on (① V2 or V3 lead: male\<40 years ≥ 0.25mV, ≥ 40 years ≥ 0.2mV; Female ≥1.5mV;② Other leads ≥ 1mV), or new left bundle branch block occurs;
  4. Criminal blood vessels with clear requirements for emergency PCI;
  5. Coronary artery in situ lesions, with a visual reference lumen diameter of ≥ 2mm and ≤ 4mm; Lesion's length\<40mm;
  6. After thrombus aspiration and pre dilation, the lesion stenosis is ≤ 50% and there is no C-type or above dissection.
  7. He/she or his/her legal representative voluntarily participates in this study and signs an form.

Exclusion criteria

Exclusion Criteria:

  1. The patient has allergies or to the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Cilostazol, Indobufen, Contrast Medias (Patients with clear contrast agent allergies such as rash but can be controlled with effective drugs such as and diphenhydramine in advance can be selected);
  2. The patient has active pathological bleeding;
  3. History of significant gastrointestinal or urogenital bleeding or bleeding tendency within 3 months prior to surgery, known coagulation disorders (including heparin induced thrombocytopenia);
  4. Patients who are pregnant or have the intention to become pregnant during the period of research;
  5. Non cardiogenic combined lesions show an expected of less than one year;
  6. Left main trunk's stenosis ≥ 50%
  7. History of coronary artery bypass grafting in the past;
  8. Intubation or mechanical ventilation status;
  9. . Cardiogenic Shock
  10. . Without signature on
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,244 participants (estimated)

Study arms

  • Experimental
    DCB group

    STEMI patients undergo revascularization using DCB

    Device: Drug-coated balloon (DCB)

  • Active comparator
    DES group

    STEMI patients undergo revascularization using DES

    Device: Drug-eluting stent (DES)

Interventions

  • DeviceDrug-coated balloon (DCB)

    Drug-coated balloon treatment of target lesions in patients with STEMI undergoing percutaneous coronary intervention.

  • DeviceDrug-eluting stent (DES)

    Drug-eluting stent treatment of target lesions in patients with STEMI undergoing percutaneous coronary intervention.

06

What researchers measure

Primary outcomes

  1. Incidence of patient-oriented composite endpoints (POCE) (Direct measurement and coronary angiography)

    POCE including all-cause mortality, any stroke, any myocardial infarction (MI), and any revascularization, will be obtained through follow-up of subjects.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of patient-oriented composite endpoints (POCE) (Direct measurement and coronary angiography)

    POCE including all-cause mortality, any stroke, any myocardial infarction (MI), and any revascularization, will be obtained through follow-up of subjects.

    Time frame: 36 months, 60 months

  2. Incidence of target vessel failure (Direct measurement and coronary angiography)

    Target vessel failure (a composite of cardiac death, target-vessel MI, or target vessel revascularization) will be obtained through follow-up of subjects.

    Time frame: 12 months

  3. Incidence of all-cause mortality (Direct measurement)

    All-cause mortality will be obtained through follow-up of subjects.

    Time frame: 36 months, 60 months

  4. Incidence of non-fatal MI (Direct measurement)

    Non-fatal MI will be obtained through follow-up of subjects.

    Time frame: 36 months, 60 months

  5. Incidence of any revascularization (coronary angiography)

    Any revascularization will be obtained through follow-up of subjects.

    Time frame: 36 months, 60 months

  6. Incidence of all-cause and cardiac death (Direct measurement)

    All-cause and cardiac death will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  7. Incidence of any non-fatal MI without peri-procedural MI (Direct measurement)

    Any non-fatal MI without peri-procedural MI will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  8. Incidence of any non-fatal MI with peri-procedural MI (Direct measurement)

    Any non-fatal MI with peri-procedural MI will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  9. Incidence of any target vessel/lesion revascularization (Coronary angiography)

    Any target vessel/lesion revascularization will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  10. Incidence of any non-target vessel/lesion revascularization (Coronary angiography)

    Any non-target vessel/lesion revascularization will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  11. Incidence of any revascularization (ischemia-driven or all) (Coronary angiography)

    Any revascularization (ischemia-driven or all) will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  12. Incidence of non-fatal stroke (ischemic and hemorrhagic) (Direct measurement)

    Non-fatal stroke (ischemic and hemorrhagic) will be obtained through follow-up of subjects.

    Time frame: 12 months, 36 months, 60 months

  13. CRP and POCE

    Prognostic value of CRP on POCE

    Time frame: 12 months, 36 months, 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2032, 79 months after the start.

Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 79 months is above that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 19, 2024
StartActual
May 31, 2025
Primary completionEst.
Jan 1, 2032
CompletionEst.
Jan 1, 2032
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    + 4 other changes: identifiers, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06742125
Collaborators
The First Affiliated Hospital of Zhengzhou University, Peking University First Hospital, Suzhou Municipal Hospital, First Affiliated Hospital of Ningbo University
Responsible party
Sponsor
First posted
Dec 19, 2024
Start date
May 31, 2025
Primary completion
Jan 1, 2032 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
Sep 28, 2026

Study contacts

Jucheng Zhang
Contact
jucheng@zju.edu.cn
+8618768146640
Jun Jiang
study director · Second Affiliated Hospital, Zhejiang University, School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion